补肾活血通络方治疗老年慢性再生障碍性贫血34例临床研究

Clinical study on Bushen Huoxue Tongluo Recipe used in treatment of 34 cases of old patients with chronic aplastic anemia

目的观察补肾活血通络方治疗老年慢性再生障碍性贫血(CAA)的临床疗效,探讨其作用机制。方法将67例老年CAA患者随机分为治疗组(34例)和对照组(33例)。治疗组用补肾活血通络方加常规西药治疗,对照组单用常规西药治疗。并分别于治疗前后采用酶联免疫吸附双抗体夹心(ELISA)法检测骨髓细胞凋亡状况。结果治疗组与对照组的基本治愈率、缓解率、总有效率分别为41.18%、23.52%、85.29%和21.21%、18.19%、60.61%。两组疗效比较差异有显著性(P<0.01)。治疗前两组骨髓细胞凋亡指数较健康对照组明显增高(P<0.01),治疗后治疗组骨髓细胞凋亡指数较治疗前明显减低(P<0.01),与对照组比较差异有显著性(P<0.01)。结论补肾活血通络方治疗老年CAA疗效可靠、不良反应少。其作用机制可能是通过阻抑老年CAA患者骨髓造血细胞的过度凋亡,从而实现骨髓造血功能恢复重建。

Objective To investigate the therapeutic effect of Bushen Huoxue Tongluo （BSHXTL） Recipe on chronic aplastic anemia （CAA） in old patients and to explore its mechanism. Methods 67 old patients with CAA were randomly divided into treated group （34 cases） and control group （33 cases）. The treated group was treated with BSHXTL recipe plus routine western medicine,while control group was treated with western medicine alone to examine respectively the apoptosis of bone marrow cells with enzyme-linked double antibody sandwich immunospecific assay （ELISA）before and after treatment. Results The cure rate, remission, total effective rate of treated group were 41.18% ,23.52% ,85. 29% respectively. Those of the control group were 21.21% , 18. 19% ,60. 61% respectively. There was significant difference between the two groups in the therapeutic effect （P 〈0. 01 ）. Apoptotic indexes in bone marrow cells in two groups before treatment were higher than that in healthy control group （P 〈0. 01 ）. In treated group,apoptotic indexes in bone marrow cells after treatment were sig- nificantly lower than that before treatment （ P 〈0. 01 ） ,there was significant difference compared with that of control group （ P 〈0. 01 ）. Condusions The therapeutic effect of BSHXTL recipe on old patients in CAA is reliable,and its side effect is small The therapeutic mechanism of BSHXTL recipe in treating old patients with CAA could inhibit over-apoptosis of the bone marrow cells so as to promote bone marrow to rebuild hematopoietic function.